Skip to main content
. 2020 Oct 6;8(19):4280–4285. doi: 10.12998/wjcc.v8.i19.4280

Table 1.

Randomized clinical trials ongoing on promising inflammatory strategy

Target Drug type Drugs
IL 6 signaling Anti-IL 6 Clazakizumab, Siltuximab
Anti-IL6 receptor Sarilumab, Tocilizumab
IL 1 signaling Anti-IL1β Canakinumab
Anti-IL1 repector Anakinra
JAK-STAT signaling JAK1/JAK2 inhibitors Baricitinib, Ruxolitinib
JAK1/JAK3 inhibitors Tofacitinib

JAK-STAT: The Janus kinase/signal transducer and activator of tran-ions; IL: Interleukin.